Influence of the Circadian Timing System on Tacrolimus Pharmacokinetics and Pharmacodynamics After Kidney Transplantation

被引:14
|
作者
Fontova, Pere [1 ,2 ,3 ]
Colom, Helena [4 ]
Rigo-Bonnin, Raul [2 ,5 ]
van Merendonk, Lisanne N. [1 ,2 ,3 ]
Vidal-Alabro, Anna [1 ,2 ,3 ]
Montero, Nuria [1 ,2 ,3 ]
Melilli, Edoardo [1 ,2 ,3 ]
Meneghini, Maria [1 ,2 ,3 ]
Manonelles, Anna [1 ,2 ,3 ]
Cruzado, Josep M. [1 ,2 ,3 ]
Torras, Juan [1 ,2 ,3 ]
Grinyo, Josep Maria [1 ,2 ,3 ]
Bestard, Oriol [1 ,2 ,3 ]
Lloberas, Nuria [1 ,2 ,3 ]
机构
[1] Bellvitge Univ Hosp, Nephrol Dept, Barcelona, Spain
[2] Inst Invest Biomed Bellvitge, Nephrol & Transplantat, Barcelona, Spain
[3] Univ Barcelona, Dept Clin Sci, Barcelona, Spain
[4] Univ Barcelona, Sch Pharm, Dept Pharm & Pharmaceut Technol, Biopharmaceut & Pharmacokinet Unit, Barcelona, Spain
[5] Univ Bellvitge, Bellvitge Univ Hosp, Biochem Dept, Inst Invest Biomed Bellvitge, Barcelona, Spain
关键词
tacrolimus; pharmacodynamic; pharmacokinetics; circadian rhythm; kidney transplantation; immunosuppression; BLOOD MONONUCLEAR-CELLS; MULTIDRUG-RESISTANCE GENE; CYCLOSPORINE; LIVER; METABOLISM; ABSORPTION; CHRONOPHARMACOKINETICS; PHARMACOGENETICS; POLYMORPHISMS; EXPRESSION;
D O I
10.3389/fphar.2021.636048
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Tacrolimus is the backbone immunosuppressant after solid organ transplantation. Tacrolimus has a narrow therapeutic window with large intra- and inter-patient pharmacokinetic variability leading to frequent over- and under-immunosuppression. While routine therapeutic drug monitoring (TDM) remains the standard of care, tacrolimus pharmacokinetic variability may be influenced by circadian rhythms. Our aim was to analyze tacrolimus pharmacokinetic/pharmacodynamic profiles on circadian rhythms comparing morning and night doses of a twice-daily tacrolimus formulation. Methods: This is a post-hoc analysis from a clinical trial to study the area under curve (AUC) and the area under effect (AUE) profiles of calcineurin inhibition after tacrolimus administration in twenty-five renal transplant patients. Over a period of 24 h, an intensive sampling (0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 12.5, 13, 13.5, 14, 15, 20, and 24 h) was carried out. Whole blood and intracellular tacrolimus concentrations and calcineurin activity were measured by UHPLC-MS/MS. Results: Whole blood and intracellular AUC(12-24 h) and C-max achieved after tacrolimus night dose was significantly lower than after morning dose administration (AUC(0-12 h)) (p < 0.001 for both compartments). AUE(0-12 h) and AUE(12-24 h) were not statistically different after morning and night doses. Total tacrolimus daily exposure (AUC(0-24 h)), in whole blood and intracellular compartments, was over-estimated when assessed by doubling the morning AUC(0-12 h) data. Conclusion: The lower whole blood and intracellular tacrolimus concentrations after night dose might be influenced by a distinct circadian clock. This significantly lower tacrolimus exposure after night dose was not translated into a significant reduction of the pharmacodynamic effect. Our study may provide conceptual bases for better understanding the TDM of twice-daily tacrolimus formulation.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation
    Yu, Meng
    Liu, Mouze
    Zhang, Wei
    Ming, Yingzi
    CURRENT DRUG METABOLISM, 2018, 19 (06) : 513 - 522
  • [2] Tacrolimus Exposure and Mycophenolate Pharmacokinetics and Pharmacodynamics Early After Liver Transplantation
    Saeves, Ingjerd
    Line, Pal-Dag
    Bremer, Sara
    Vethe, Nils T.
    Tveit, Ragnhild G.
    Meltevik, Tore J.
    Bergan, Stein
    THERAPEUTIC DRUG MONITORING, 2014, 36 (01) : 46 - 53
  • [3] Modelling changes in the pharmacokinetics of tacrolimus during pregnancy after kidney transplantation: A retrospective cohort study
    Schagen, Maaike R.
    Ulu, Asiye Nur
    Francke, Marith I.
    van de Wetering, Jacqueline
    van Buren, Marleen C.
    Schoenmakers, Sam
    Matic, Maja
    van Schaik, Ron H. N.
    Hesselink, Dennis A.
    de Winter, Brenda C. M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (01) : 176 - 188
  • [4] Influence of the Cyp3a5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients
    Ferraresso, Mariano
    Tirelli, Amedea
    Ghio, Luciana
    Grillo, Paolo
    Martina, Valentina
    Torresani, Erminio
    Edefonti, Alberto
    PEDIATRIC TRANSPLANTATION, 2007, 11 (03) : 296 - 300
  • [5] Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation
    Chakkera, H. A.
    Chang, Y-H
    Bodner, J. K.
    Behmen, S.
    Heilman, R. L.
    Reddy, K. S.
    Mulligan, D. C.
    Moss, A. A.
    Khamash, H.
    Katariya, N.
    Hewitt, W. R.
    Pitta, T. L.
    Frassetto, L. A.
    TRANSPLANTATION PROCEEDINGS, 2013, 45 (01) : 137 - 141
  • [6] The Tacrolimus Metabolism Rate and Dyslipidemia after Kidney Transplantation
    Thoelking, Gerold
    Schulte, Christian
    Jehn, Ulrich
    Schuette-Nuetgen, Katharina
    Pavenstaedt, Hermann
    Suwelack, Barbara
    Reuter, Stefan
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (14)
  • [7] Pharmacokinetics and Pharmacodynamics of Once-Daily Tacrolimus Compared With Twice-Daily Tacrolimus in the Early Stage After Living Donor Liver Transplantation
    Iwasaki, Mami
    Yano, Ikuko
    Fukatsu, Sachio
    Hashi, Sachiyo
    Yamamoto, Yuki
    Sugimoto, Mitsuhiro
    Fukudo, Masahide
    Masuda, Satohiro
    Nakagawa, Shunsaku
    Yonezawa, Atsushi
    Kaido, Toshimi
    Uemoto, Shinji
    Matsubara, Kazuo
    THERAPEUTIC DRUG MONITORING, 2018, 40 (06) : 675 - 681
  • [8] Risk of Tacrolimus Toxicity in CYP3A5 Nonexpressors Treated With Intravenous Nicardipine After Kidney Transplantation
    Hooper, David K.
    Fukuda, Tsuyoshi
    Gardiner, Rhonda
    Logan, Barbara
    Roy-Chaudhury, Ashwini
    Kirby, Cassie L.
    Vinks, Alexander A.
    Goebel, Jens
    TRANSPLANTATION, 2012, 93 (08) : 806 - 812
  • [9] Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation
    Christine E. Staatz
    Susan E. Tett
    Clinical Pharmacokinetics, 2004, 43 : 623 - 653
  • [10] The Tacrolimus Metabolism Rate Influences Renal Function After Kidney Transplantation
    Thoelking, Gerold
    Fortmann, Christian
    Koch, Raphael
    Gerth, Hans Ulrich
    Pabst, Dirk
    Pavenstaedt, Hermann
    Kabar, Iyad
    Huesing, Anna
    Wolters, Heiner
    Reuter, Stefan
    Suwelack, Barbara
    PLOS ONE, 2014, 9 (10):